LuxCath, an Allied Minds company, announced this week the promising results of their namesake system in its first-in-man study. The LuxCath utilizes optical technology to directly characterize tissue during cardiac ablation procedures (which are a common, minimally invasive treatment to correct arrhythmias). In essence, the novel catheter-embedded system uses light to visualize the cardiac tissue beneath the surface of the heart. In doing so, the LuxCath provides valuable real-time feedback to the physician regarding tissue contact and lesion formation that, in practice, hopes to facilitate procedure speed, safety, and effectiveness.
LuxCath is initially targeting ablation procedures designed to treat Atrial Fibrillation. The preliminary clinical study, conducted in Prague on eleven patients, supported the system’s ability to aid in the prevention of gaps of viable tissue linking lesions. Ultimately, LuxCath intends to offer their technology embedded within standard ablation catheters without significantly raising their costs.
Company Page: LuxCath…
Source: Press Release…